title: [Permanent implant prostate cancer brachytherapy].
abstract: With an experience of more than 20 years for the pionneers (and more than 10 years in France), permanent implant brachytherapy using Iodin 125 seeds is now recognized as a valuable alternative therapy for localized low-risk prostate cancer patients. An extension of the indications of exclusive brachytherapy towards selected patients in the intermediate-risk group is presently under study. Moreover, for patients in the high-risk group, brachytherapy, as an addition to external radiotherapy, could represent one of the best way to escalate the dose for some patients. Various permanent implant brachytherapy techniques have been proposed; preplanning or real-time techniques, loose seeds or stranded seeds, manual or automatic injection of the seeds. The main point here is the ability to perfectly master the procedure and to comply with the dosimetric constraints which have been recently redefined by the Groupe européen de curiethérapie--European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) group. Mid- and long-term results which are now available in the literature indicate relapse-free survival of about 90% at 5-10 years, the best results being obtained with satisfactory dosimetric data. Some comparative data have shown that the incontinence and impotence rates after brachytherapy seemed to be significantly inferior to what is currently observed after surgery. However, a risk of about 3-5% of urinary retention is usually reported after brachytherapy, as well as an irritative urinary syndrome which may be significant and last several months. In spite of those drawbacks, with excellent long-term results and low rates of incontinence and impotence, brachytherapy can be expected to be proposed to an increasing number of patients in France in the next future.
authors.affiliation: Département d'oncologie et radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. jean-marc.cosset@curie.net
authors.forename: J-M
authors.initials: JM
authors.lastname: Cosset
authors.forename: T
authors.initials: T
authors.lastname: Flam
authors.forename: N
authors.initials: N
authors.lastname: Thiounn
authors.forename: D
authors.initials: D
authors.lastname: Pontvert
authors.forename: N
authors.initials: N
authors.lastname: Pierrat
authors.forename: G
authors.initials: G
authors.lastname: Vallancien
authors.forename: L
authors.initials: L
authors.lastname: Chauveinc
mesh_terms: D001331:Automation; D001918:Brachytherapy / Q000379:methods*; D006801:Humans; D008297:Male; D019935:Penile Implantation / Q000379:methods*; D015917:Penile Prosthesis; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods; D011879:Radiotherapy Dosage